APOE4, Vitamin D, Grip Strength, and Dementia Risk

APOE4 raises dementia risk, but it does not make every carrier's future identical. In a large UK Biobank cohort, APOE e4 carriers who started with higher vitamin D status and stronger handgrip had lower observed dementia incidence than carriers with low vitamin D and weak grip. That is a useful risk signal. It is not proof that vitamin D supplements or grip exercises can cancel genetic risk.

The distinction matters because the tempting version of this story sells a simple fix for a complicated disease. The actual study shows that vitamin D status and grip strength may help identify which APOE e4 carriers look more vulnerable over time. It cannot tell us whether changing either measurement would change anyone's dementia outcome.

What the UK Biobank study found

Feng et al.'s 2023 prospective cohort study followed 165,688 UK Biobank participants for a median of 12.0 years and identified 3,917 incident dementia cases. At recruitment, researchers measured blood 25-hydroxyvitamin D, tested handgrip strength, and classified APOE genotype. Their main question was whether these baseline measures jointly tracked later dementia risk.

Among APOE e4 carriers, women in the highest vitamin D tertile and highest sex-specific grip-strength tertile had a lower dementia hazard than women in the lowest tertiles for both measures: hazard ratio 0.56, 95% confidence interval 0.42 to 0.76. The equivalent result in men was 0.48, 95% CI 0.36 to 0.64. These comparisons were statistically significant because neither confidence interval included 1.0.

The absolute-risk contrast makes the result easier to picture. Within APOE e4 carriers, the estimated 15-year cumulative dementia incidence was 6.4% (95% CI 5.9% to 7.0%) in the low-vitamin-D, low-grip group and 2.4% (95% CI 2.1% to 2.7%) in the high-vitamin-D, high-grip group.

APOE e4 still mattered. Compared with APOE e4 noncarriers who had low vitamin D and low grip, APOE e4 carriers in that same low/low group had much higher dementia risk: hazard ratio 4.29 (95% CI 3.52 to 5.22) in women and 2.62 (95% CI 2.20 to 3.14) in men. Better baseline measurements did not erase genetic risk; they identified a lower-risk subgroup within a genetically vulnerable population.

An interaction signal, not a treatment result

The study's interaction findings were strongest on the additive scale. For the combination of APOE e4, low vitamin D, and low grip strength, the relative excess risk due to interaction was 2.868 (95% CI 1.048 to 4.688) in women and 2.020 (95% CI 0.460 to 3.581) in men. The corresponding attributable proportions were 0.352 in women and 0.262 in men.

Put simply, low vitamin D and weak grip clustered with higher observed dementia risk in APOE e4 carriers more than a simple addition of separate risks would predict. That pattern can help stratify risk. It does not identify a biological switch that a supplement can flip.

"High" in this analysis also did not mean a clinical vitamin D target or a prescribed strength program. It meant the highest baseline tertile of serum 25-hydroxyvitamin D and the highest sex-specific tertile of grip strength. Researchers measured vitamin D once, between 2006 and 2010, and derived grip strength from one maximal three-second effort in each hand.

Why grip deserves attention, with restraint

Handgrip strength is an accessible measure of physical capability, and several studies link poorer physical function with later cognitive trouble. In a related UK Biobank prospective cohort study, walking pace and handgrip strength were examined alongside age and APOE genotype in relation to new-onset dementia. The finding supports grip as a practical vulnerability marker across genetic backgrounds, but it does not prove that stronger hands protect the brain.

A longitudinal English aging study also linked baseline sarcopenia—low grip strength plus low predicted muscle mass—to worse later cognitive performance. Meanwhile, a 2025 meta-analysis found sarcopenia or probable sarcopenia was common among middle-aged and older adults with cognitive impairment. These findings fit a broader picture: muscle decline and cognitive decline often travel together.

They may also travel in both directions. In the English Longitudinal Study on Ageing, mild cognitive impairment predicted later sarcopenia in 3,106 participants, with an odds ratio of 1.236 (95% CI 1.090 to 1.596; p=0.01). That reverse-direction study weakens any neat claim that weak grip sits entirely upstream of dementia. Early cognitive decline can reduce activity, diet quality, time outdoors, and physical function long before a formal dementia diagnosis.

What randomized trials can—and cannot—add

Randomized multidomain programs provide more encouraging evidence for improving some physical and cognitive outcomes, though not for preventing dementia in APOE4 carriers. A 2024 systematic review and meta-analysis of randomized trials found that multidomain interventions in older adults produced modest improvements in cognitive flexibility and sit-to-stand performance.

In a 12-month cluster-randomized trial of 733 community-dwelling older adults, a multidomain intervention improved cognition among participants with physio-cognitive decline syndrome and improved handgrip strength in that subgroup. A separate randomized secondary analysis in 340 older adults found a 1.1-point improvement in global MoCA score among participants with that syndrome (95% CI 0.4 to 1.8; p=0.003). Those trial results show that combined programs can improve selected outcomes in selected older populations.

They did not test vitamin D as a dementia-prevention treatment. They did not test grip training alone. They did not show that an APOE e4 carrier who raises grip strength or vitamin D will reduce future dementia incidence. Those are different questions, and good science does not pretend they are interchangeable.

Vitamin D is the least settled part of the story

The primary cohort study itself argues against a simple "higher is better" vitamin D narrative. The authors reported a U-shaped association between vitamin D and dementia risk in men, meaning both low and high values may not map neatly to lower risk in every comparison. Among female APOE e4 noncarriers, the high-versus-low vitamin D comparison was not statistically significant: hazard ratio 0.91, 95% CI 0.76 to 1.08.

Vitamin D also changes with season, sunlight exposure, illness, diet, and supplementation. One baseline blood sample cannot capture a person's long-term status. The study assigned values below detection to 10 nmol/L and capped extreme high values at 125 nmol/L, choices that may reduce measurement precision. Its available methods do not clearly describe seasonal adjustment, another concern for an exposure that fluctuates with sunlight.

Large cohorts have linked healthier behavior patterns with lower dementia incidence. For example, a prospective UK Biobank study found that replacing leisure-time sedentary behavior with physical activity was associated with lower dementia incidence and mortality. Another large cohort examined physical activity, grip strength, sedentary time, sleep, and genetic risk together, placing muscle strength inside a broader lifestyle pattern rather than treating it as a lone anti-dementia tool.

The practical verdict

For APOE4 carriers, vitamin D status and grip strength are reasonable measures to monitor as part of a broader healthy-aging assessment. The cohort data show a meaningful risk gradient: carriers with high baseline vitamin D and high grip had lower observed dementia incidence than those with low values for both.

But do not translate that association into a supplement prescription or a claim that handgrip training neutralizes APOE4. The central evidence is observational, both exposures were measured once, dementia ascertainment relied on self-report plus hospital and death records, and reverse causation remains plausible despite analyses excluding cases and deaths within the first three years. Maintain physical capability, address vitamin D deficiency with a clinician when appropriate, and treat neither measurement as genetic risk insurance.